Description
Retatrutide is a synthetic triagonist peptide that simultaneously targets the glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR). It is designated a GLP-1/GIP/Glucagon triple receptor agonist in preclinical literature.
Current research interest centers on retatrutide’s multi-receptor activity profile and its effects on energy homeostasis, lipid metabolism, and glycemic regulation in in-vitro and animal model settings. Peer-reviewed preclinical studies have examined its receptor binding kinetics and downstream signaling pathways across all three target receptors.
Supplied as: Lyophilized powder, sealed vial
Purity: ≥99% (HPLC verified)
Testing: Independent third-party mass spectrometry and HPLC per batch
Storage: −20°C, away from light and moisture
Reconstitution: Bacteriostatic water (not included)
For research use only. Not for human or animal administration. Must be handled by a qualified researcher in a licensed laboratory setting. This product is not approved by the FDA and is not intended for diagnostic or therapeutic use.
